High-dose chemotherapy followed by ASCT is a widely used treatment for agressive or recurrent NHL for young patients (pts). Limited data are available on the feasibility and the results of this strategy for older pts, who are often excluded from agressive treatment. This study aimed at comparing pts ≥65 years old(yo) to a younger pts’ population in term of tolerance, safety and results of ASCT.
We did a retrospective study in one center in France. We included every consecutive pts treated by ASCT for NHL from May 2007 to January 2016. We collected data on the characteristics of the pts and their disease, previous treatments, and tolerance and outcome after ASCT.
48 pts ≥ 65 yo (mean: 49.5) and 129 < 65 yo (mean: 68.7) at the time of the transplant were included. The most common histology was diffuse large B cell lymphoma (p = 0.205). There were only 2 differences between the 2 groups. First, the number of pts with comorbidities was higher in the elderly population (p = 0.016), especially cardio-vascular (p
High-dose chemotherapy followed by ASCT is as safe and effective in a population of pts ≥65 yo compared to a younger population. Agressive treatment could be considered earlier in the management of elderly pts and should not be excluded only depending on the age of the patient.
Clinical trial identification
Legal entity responsible for the study
Centre antoine Lacassagne
All authors have declared no conflicts of interest.